The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells

References

• Appert-Collin A, Hubert P, Crémel G, Bennasroune A. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015;6:283. doi:10.3389/fphar.2015.00283. PMID:26635612.
   PubMed Web of Science ®Google Scholar
• Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother. 2016;12:576–92 doi:10.1080/21645515.2015.1102809. PMID:26529100.
   PubMed Web of Science ®Google Scholar
• Martinello R, Milani A, Geuna E, Zucchini G, Aversa C, Nuzzo A, Montemurro F. Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2016;25:393–403. doi:10.1517/13543784.2016.1153063. PMID:26863927.
   PubMed Web of Science ®Google Scholar
• Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Curr Cancer Drug Targets. 2015;14:775–93. doi:10.2174/1568009614666141111104643. PMID:25435079.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget. 2017;8:90262–90277. PMID:29163826.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol. Ther. IN PRESS doi:10.1080/15384047.2017.1394556.
   Google Scholar
• Zhang Y, Zhang J, Liu C, Du S, Feng L, Luan X, Zhang Y, Shi Y, Wang T, Wu Y, Cheng W, Meng S, Li M, Liu H. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 2016;382:176–185. doi:10.1016/j.canlet.2016.08.026. PMID:27597738.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Konopleva M, Ravandi F. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. Expert Rev Hematol. 2017;10:863–874. doi:10.1080/17474086.2017.1366852. PMID:28799432.
   PubMed Web of Science ®Google Scholar
• Radha G, Raghavan SC. BCL2: A promising cancer therapeutic target. Biochim Biophys Acta. 2017;1868:309–314. PMID:28647470.
   PubMed Web of Science ®Google Scholar
• Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, Banu M, Roth KA, Bruce JN, Canoll P, Altieri DC, Siegelin MD. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res. 2017;77:3513–3526 doi:10.1158/0008-5472.CAN-16-3424. PMID:28522750.
   PubMed Web of Science ®Google Scholar
• Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. 2016;7:27946–58. doi:10.18632/oncotarget.8547. PMID:27056887.
   PubMed Web of Science ®Google Scholar
• Webb T, Carter J, Roberts JL, Poklepovic A, McGuire WP, Booth L, Dent P. Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. Cancer Biol Ther. 2015;16:1660–70. doi:10.1080/15384047.2015.1099769. PMID:26417912.
   PubMed Web of Science ®Google Scholar
• Kennedy D, Mnich K, Oommen D, Chakravarthy R, Almeida-Souza L, Krols M, Saveljeva S, Doyle K, Gupta S, Timmerman V, Janssens S, Gorman AM, Samali A. HSPB1 facilitates ERK-mediated phosphorylation and degradation of BIM to attenuate endoplasmic reticulum stress-induced apoptosis. Cell Death Dis. 2017;8:e3026.
   PubMed Web of Science ®Google Scholar
• Shi P, Oh YT, Deng L, Zhang G, Qian G, Zhang S, Ren H, Wu G, Legendre B Jr, Anderson E, Ramalingam SS, Owonikoko TK, Chen M, Sun SY. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clin Cancer Res. 2017;23:6567–6579. doi:10.1038/cddis.2017.408. PMID:28765329.
   PubMed Web of Science ®Google Scholar
• Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010;29:1717–9.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol. 2006;70:589–603. doi:10.1038/onc.2009.519. PMID:16622074.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Can. Ther. 2007;6:3101–12. doi:10.1158/1535-7163.MCT-07-0561.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. Oncotarget 2017. IN PRESS. doi:10.18632/oncotarget.23681.
   Google Scholar